- Telo Genomics has kick-started its clinical trial for multiple myeloma patients having now received the first patient sample from the trial
- The study is being done in collaboration with McGill University and the Jewish General Hospital in Montreal
- The trial will focus on diagnosed multiple myeloma patients who are eligible for bone marrow transplantation
- Shares of Telo Genomics are unchanged at C$0.16 but are down 15.79 per cent year-to-date
Telo Genomics (TSXV:TELO) has officially kick-started its clinical trial for multiple myeloma patients having now received the first patient sample from the trial.
The company stated in a news release that the trial is being conducted through a collaboration with McGill University and the Jewish General Hospital in Montreal and will focus on patients diagnosed with multiple myeloma who are eligible for bone marrow transplantation.
The study will also aim to measure and profile the measurable residual disease (MRD) – which are cancer cells that are still in a patient’s system post-treatment – in patients post-transplantation.
“We are very excited to receive the first patient sample for our MRD study,” Sherif Louis, president and CTO of Telo Genomics, said in a statement. “Telo’s sensitive methodology provides a unique advantage in the profiling of MRD cells on an individual basis; it has the potential to fill a critical gap in analysis of MRD and inform on disease aggressiveness, allowing clinicians to take full advantage of its prognostic power.”
The company’s MRD study has two key objectives for the potential development of two prognostic tests for monitoring myeloma MRD, including:
- identifying and quantifying the number of MRD cells in a patient’s blood post-marrow transplantation over time
- profiling the isolated circulating MRD cells using TeloView’s technology to assess disease aggressiveness in each MRD cell
According to the company, MRD testing has become crucial in assessing treatment response and assisting therapeutic decisions in oncology.
Based out of Toronto, Telo Genomics is focused on developing liquid biopsies and related technologies for oncology and neurological conditions.
Shares of Telo Genomics are unchanged at C$0.16 but are down 15.79 per cent year-to-date.
Join the discussion: Find out what everybody’s saying about this stock on the Telo Genomics Bullboard investor discussion forum, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.